Bone out-licenses cell therapy platform in China and Southeast Asia

5 October 2020

Bone Therapeutics has signed an exclusive license agreement with Link Health and Shenzhen Pregene Biopharma for the manufacturing, clinical development and commercialization of its allogeneic, off-the-shelf, bone cell therapy platform ALLOB in China, Taiwan, Singapore, South Korea, and Thailand.

Under the agreement, Bone is eligible to receive up to 55 million euros ($65 million) in development, regulatory and commercial milestone payments including 10 million euros in upfront and milestone payments anticipated in the next 24 months.

Bone is also entitled to receive tiered double-digit royalties on annual net sales of ALLOB. The Belgian firm retains development and commercialization rights in all other geographies outside of those covered by this agreement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK